President Donald Trump is getting a single 8-gram dose of an experimental antibody "cocktail" and antiviral drug Remdesivir to treat Covid-19.
The cocktail is produced by, a New York-based biotech company Regeneron who confirmed providing the drug what's commonly known as a "compassionate use" upon getting requests from the President's physicians, reports CNN.
The therapy is known as REGN-COV2; the company calls it a "cocktail" of two monoclonal antibodies.
Polyclonal antibodies are made using several different immune cells, while monoclonal antibodies are made using identical immune cells that are clones of a specific parent cell. To make its monoclonal antibody therapy, Regeneron scientists selected two antibodies that best neutralised a version of the novel coronavirus in the lab. They then cloned these antibodies and put it into a treatment. Regeneron is using two antibodies since they think it will work best as the virus mutates.
Outside infectious disease experts said the early results looked "very promising," but they would need to see results from a larger number of patients.
On Tuesday, the company announced results from the first 275 non-hospitalized patients in a late-stage trial that showed that the treatment was safe and seemed to reduce viral levels and improve symptoms in patients with Covid-19.
Apart from that, one of the most potent drugs to treat Covid-19 until now, the antiviral drug Remdesivir is also being given to treat the President.
The drug began being used in "about three hospitals in the north" last weekend as part of Oxford University's national Recovery trial, said Professor Peter Horby from Oxford University.
"This particular drug has probably been given to, I would think now, four or five hundred patients, mild or severe patients in different trials, and so far there's been no worrying safety signals," he added.